Investor Relations
Deep-tech research demands patient capital. Atumics is built for the investors who understand that the most valuable companies are the ones that solve the hardest problems.
Founder-Led from Day One
Atumics was founded by Morten Skaersoe and Thomas Munkholm. Skaersoe is a particle physicist — PhD from the University of Copenhagen, six years at CERN on the ATLAS experiment, co-founder of a nuclear energy startup, and former Director of AI at a major Nordic defense group. He brings the scientific vision: the conviction that atomic-scale control of matter is both achievable and morally necessary.
Munkholm is the builder. An economist by training, he spent over a decade scaling a precision radar and defense technology company from 45 to over 500 employees, serving as owner, chairman, and chief operating officer. He understands how to turn deep-tech research into products, production lines, and revenue — and how to build the organizations that sustain it.
Together they represent the two competencies Atumics was designed to fuse: the physicist who can see what is possible, and the industrialist who can make it real. Both remain hands-on. Skaersoe still leads research reviews and drives the architectural decisions that shape every programme. Munkholm oversees operations, partnerships, and the commercial strategy that translates breakthroughs into deployable systems.
The Case for Long-Term Deep-Tech Capital
The venture capital model was designed for software companies that can reach product-market fit in 18 months. Deep-tech hardware, materials science, and nuclear engineering operate on fundamentally different timescales. Atumics' HEARTH reactor required six years from concept validation to prototype power output. ZEPHYR required four years from first flight to medium-platform demonstration.
But the moats are correspondingly deeper. Software can be replicated by a team of ten in a garage. A validated subcritical nuclear reactor, a quantum sensor array at the Heisenberg limit, and a programmable matter framework with 200 validated atomic components cannot. These are assets measured in decades of accumulated knowledge, not lines of code.
Atumics seeks investors who understand this asymmetry: longer development cycles in exchange for wider moats, deeper defensibility, and the potential to create entirely new categories of technology.
Key Financials (2037)
Revenue Streams
- • AEGIS system sales & service contracts
Defense and civilian deployments across NATO member states - • SpectraLens sensor module sales
Commercial, scientific, and space-qualified variants - • APF platform licensing
~140 institutional licenses at recurring annual fees - • Gluino integration services
Enterprise manufacturing automation and process control - • ZEPHYR-S propulsion modules
Commercial and defense UAV platform sales - • Patent licensing & technology transfer
Cross-licensing agreements across 14 partner organizations - • Research grants & government contracts
DARPA, EDF, Horizon Europe, and bilateral agreements
Financial Highlights
Sovereign Wealth Fund Partnerships
In 2037, Atumics closed a strategic sovereign investment round, bringing capital from allied sovereign wealth funds. These investors were selected not for the size of their commitment but for the alignment of their mandate: long-duration capital from democratic nations with an interest in maintaining technological sovereignty in critical domains.
The sovereign investment structure includes technology access provisions that align investor nations with Atumics' research output — ensuring that the countries that fund the research have priority access to its defensive and civilian applications.
We do not accept capital from investors whose interests conflict with the democratic values and export control frameworks that govern our work.